(Module 1), summaries (Module 2), quality (Module 3), nonclinical (Module 4), and clinical (Module 5).

eCTD: The electronic implementation of CTD with XML backbones for navigation and lifecycle management.

Granularity: The level at which documents are broken down and indexed within eCTD to facilitate review.

Sequence: Each eCTD submission is organized as a “sequence,” representing a lifecycle event (initial submission, amendment, supplement, or withdrawal).

Validation Criteria: Automated rules applied by regulatory agencies to ensure eCTD compliance before human review.

Regional Module: While Modules 2–5 are harmonized, Module 1 differs by country (e.g., FDA, EMA, Health Canada).

Understanding these definitions ensures regulatory professionals can prepare, publish, and validate dossiers correctly, minimizing risk of rejection or delay.

Applicable Guidelines and Global Frameworks

CTD/eCTD compilation is guided by ICH standards and local regulatory mandates. Key references include:

• ICH M4 Guidelines: Define CTD structure and content requirements across Modules 2–5.
• ICH M2 eCTD Specification: Establishes electronic technical requirements and XML standards.
• FDA eCTD Guidance: U.S. FDA mandates eCTD for all NDAs, ANDAs, BLAs, and INDs (FDA).
• EMA eSubmission Roadmap: EMA requires eCTD format for all centralised and national submissions in Europe (EMA).
• Health Canada eCTD Guidance: Mandatory for most human drug submissions since 2016 (Health Canada).
• PMDA eCTD Requirements: Japan’s PMDA requires strict compliance with eCTD technical specifications (PMDA).
• CDSCO India CTD/eCTD: India’s regulatory body increasingly requires CTD/eCTD for new drug applications (CDSCO).

These frameworks highlight the global convergence of dossier standards, though country-specific variations in Module 1 remain a major challenge for sponsors.

Processes, Workflow, and Submissions

The compilation process follows a structured workflow, combining content preparation, publishing, and validation:

1. Data Collection: Gather all quality, preclinical, and clinical documents, ensuring adherence to ICH format.
2. Module Authoring: Draft and format documents for Modules 2–5; prepare country-specific Module 1 content.
3. Publishing: Use eCTD publishing tools to convert documents into compliant formats, assign node granularity, and create XML backbones.
4. Validation: Run agency-specific validation checks to ensure technical compliance (FDA, EMA, etc.).
5. Submission: Submit via electronic gateways (FDA ESG, EMA CESP, Health Canada CESG, PMDA Gateway).
6. Lifecycle Management: Track submissions across sequences (e.g., initial, response to queries, variations, renewals).

Strict adherence to this workflow ensures submissions are technically valid, reviewable, and audit-proof, increasing the probability of first-cycle approval.

Tools, Software, or Templates Used

Regulatory publishing and submission require specialized tools. Commonly used solutions include:

• Lorenz docuBridge: Widely used eCTD publishing software.
• Extedo eCTDmanager: Comprehensive eCTD publishing and validation tool.
• eValidator (FDA/EMA): Official tools to validate submissions before sending to agencies.
• Templates: Microsoft Word templates aligned with CTD structure for authoring modules.
• XML Backbone Generators: Ensure technical structure and lifecycle management compliance.

Using validated tools reduces submission risk and ensures consistency across multiple global agencies.

Common Challenges and Best Practices

Companies frequently face obstacles during CTD/eCTD compilation:

• Granularity Errors: Incorrect document splitting leads to validation failures.
• Module 1 Variations: Differences between FDA, EMA, and other regulators complicate dossier preparation.
• Technical Rejections: Caused by XML errors or formatting inconsistencies.
• Version Control Issues: Mismanagement of document versions across lifecycle sequences.

Best practices include early planning of dossier architecture, adopting standardized templates, investing in validated publishing tools, and conducting internal mock submissions. Training teams on country-specific Module 1 differences is also essential for global readiness.

Latest Updates and Strategic Insights

In 2025, CTD/eCTD compilation continues to evolve:

• Global Mandates: Nearly all major health authorities now require eCTD, replacing paper or non-structured electronic formats.
• Artificial Intelligence (AI): Emerging AI-assisted publishing tools help automate dossier assembly and error checking.
• Lifecycle Integration: Authorities emphasize accurate tracking of sequence numbers and document replacement logic.
• Regulatory Reliance: More agencies are accepting eCTD submissions based on trusted regulator assessments, accelerating approval timelines.

Strategically, companies must invest in robust eCTD infrastructure and skilled publishing teams. Treating CTD/eCTD compilation as a compliance-critical activity ensures faster submissions, reduces rejection risks, and builds global regulatory credibility.